Lonsurf (trifluridine and tipiracil) — Medica
Appendiceal cancer
Initial criteria
- age ≥ 18 years
- advanced or metastatic disease
- Patient meets ONE of the following (i or ii):
- i. proficient mismatch repair/microsatellite-stable (pMMR/MSS) disease; OR
- ii. ineligible for or progressed on checkpoint inhibitor therapy AND meets ONE of the following (a or b):
- a) deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) disease; OR
- b) polymerase epsilon/delta (POLE/POLD1) mutation positive
- Previously treated with ALL of the following (i, ii, and iii):
- i. Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
- ii. An anti-vascular endothelial growth factor (VEGF) agent
- iii. If RAS wild-type (KRAS and NRAS mutation negative), patient meets ONE of the following (a or b):
- a) anti-epidermal growth factor receptor (EGFR) therapy NOT medically appropriate; OR
- b) received anti-EGFR therapy
Approval duration
1 year